Targeted Cancer Therapy Using Novel Biotin-Derived Platinum Analogues

Over the past few years, our work has led to the development of small-molecule cancer therapeutics. We’ve identified two compounds that show promising efficacy, both in vitro and in vivo, with selective uptake in biotin-receptor–positive solid tumors, including breast and lung cancers.
The preclinical data suggest strong potential for advancement toward IND-enabling studies and clinical trials.

We look forward to discussions with interested parties to further advance our work or for other forms of agreement with Pharma companies (licensing possibilities)

Advantages: Targeted Delivery, Efficacy in Resistant Cancers, Improved Safety Profile, Based on a known mechanism of action